Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer have been revised. It is anticipated that the appraisal will begin in early-July 2023.